Inlyta revenue trends
In 4Q17, Pfizer’s (PFE) Inlyta generated revenues of $83 million, which is a 14% decline YoY (year-over-year) and a 1% decline on a quarter-over-quarter basis.
In the US and international markets in 4Q17, Inlyta generated revenues of $31 million and $52 million, respectively—compared to $36 million and $60 million in 4Q16.
In emerging markets, Inlyta generated revenues $14 million—compared to $11 million in 4Q17, which reflected ~27% growth on a YoY basis.
In fiscal 2017, Inlyta reported revenues of $339 million, which reflected a 15% decline on a YoY basis. In 2017, in the US and international markets, Inlyta reported revenues of $126 million and $213 million, respectively—compared to $161 million and $240 million in 2016.
Inlyta (axitinib) is used to treat individuals with advanced renal cell carcinoma after a previous systemic therapy failed.
In December 2017, the FDA granted Pfizer and Merck’s Inlyta a BTD (breakthrough therapy designation) for the Inlyta and avelumab combination therapy for treatment-naïve individuals with advanced renal cell carcinoma.
The FDA granted the BTD status based on clinical data from the phase 1b JAVELIN Renal 100 trial, which evaluated the safety and efficacy of the Inlyta and avelumab combination therapy for treating individuals with advanced renal cell carcinoma who are treatment-naïve.
Previously, the FDA granted Bavencio (avelumab) BTD status to treat individuals with metastatic Merkel cell carcinoma who showed disease progression after one prior chemotherapy regimen.
About renal cell carcinoma
Renal cell carcinoma is one of the most common types of kidney cancer. Renal cell carcinoma accounts for ~90% of all kidney cancers. Globally, ~273,000 new cases of kidney cancers are diagnosed every year.
The American Cancer Society estimates ~63,340 new cases of kidney cancer in the US in 2018 with ~14,970 deaths due to kidney cancer. According to the National Cancer Institute, 11%–12% is the five-year survival rate of individuals with advanced renal cell carcinoma.